Cargando…

An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran

BACKGROUND: Cost-effectiveness analysis provides a crucial means for evidence-informed decision-making on resource allocation. This study aims to elicit individuals' willingness to pay (WTP) for one additional quality-adjusted life-year (QALY) gained from life-saving treatment and associated fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Moradi, Najmeh, Woldemichael, Abraha, Malekian, Parisa, Rotvandi, Delnia Moradi, Rezaei, Satar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585313/
https://www.ncbi.nlm.nih.gov/pubmed/33110399
http://dx.doi.org/10.1186/s12962-020-00241-9
_version_ 1783599762841272320
author Moradi, Najmeh
Woldemichael, Abraha
Malekian, Parisa
Rotvandi, Delnia Moradi
Rezaei, Satar
author_facet Moradi, Najmeh
Woldemichael, Abraha
Malekian, Parisa
Rotvandi, Delnia Moradi
Rezaei, Satar
author_sort Moradi, Najmeh
collection PubMed
description BACKGROUND: Cost-effectiveness analysis provides a crucial means for evidence-informed decision-making on resource allocation. This study aims to elicit individuals' willingness to pay (WTP) for one additional quality-adjusted life-year (QALY) gained from life-saving treatment and associated factors in Kermanshah city, western Iran. METHODS: We conducted a cross-sectional study on a total of 847 adults aged 18 years and above to elicit their WTP for one additional QALY gained by oneself and a family member using a hypothetical life-saving treatment. We used a multistage sampling technique to select the samples, and the Iranian version of EQ-5D-3L, and visual analogue scale (VAS) measures to obtain the participants’ health utility value. The Tobit regression model was used to identify the factors affecting WTP per QALY values. RESULTS: The mean WTP value and standard deviation (SD) was US$ 862 (3,224) for the respondents. The mean utility values using EQ-5D-3L and VAS methods for respondents were 0.779 and 0.800, respectively. Besides, the WTP for the additional QALY gained by the individual participants using the EQ-5D-3L and VAS methods were respectively US$ 1,202 and US$ 1,101, while the estimated value of the family members was US$ 1,355 (SD = 3,993). The Tobit regression models indicated that monthly income, education level, sex, and birthplace were statistically significantly associated (p < 0.05) with both the WTP for the extra QALY values using the EQ-5D-3L and the VAS methods. Educational level and monthly income also showed statistically significant relationships with the WTP for the additional QALY gained by the family members (p < 0.05). CONCLUSION: Our findings indicated that the participants' WTP value of the additional QALY gained from the hypothetical life-saving treatment was in the range of 0.20–0.24 of the gross domestic product (GDP) per capita of Iran. This value is far lower than the World Health Organization (WHO) recommended CE threshold value of one. This wide gap reflects the challenges the health system is facing and requires further research for defining the most appropriate CE threshold at the local level.
format Online
Article
Text
id pubmed-7585313
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75853132020-10-26 An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran Moradi, Najmeh Woldemichael, Abraha Malekian, Parisa Rotvandi, Delnia Moradi Rezaei, Satar Cost Eff Resour Alloc Research BACKGROUND: Cost-effectiveness analysis provides a crucial means for evidence-informed decision-making on resource allocation. This study aims to elicit individuals' willingness to pay (WTP) for one additional quality-adjusted life-year (QALY) gained from life-saving treatment and associated factors in Kermanshah city, western Iran. METHODS: We conducted a cross-sectional study on a total of 847 adults aged 18 years and above to elicit their WTP for one additional QALY gained by oneself and a family member using a hypothetical life-saving treatment. We used a multistage sampling technique to select the samples, and the Iranian version of EQ-5D-3L, and visual analogue scale (VAS) measures to obtain the participants’ health utility value. The Tobit regression model was used to identify the factors affecting WTP per QALY values. RESULTS: The mean WTP value and standard deviation (SD) was US$ 862 (3,224) for the respondents. The mean utility values using EQ-5D-3L and VAS methods for respondents were 0.779 and 0.800, respectively. Besides, the WTP for the additional QALY gained by the individual participants using the EQ-5D-3L and VAS methods were respectively US$ 1,202 and US$ 1,101, while the estimated value of the family members was US$ 1,355 (SD = 3,993). The Tobit regression models indicated that monthly income, education level, sex, and birthplace were statistically significantly associated (p < 0.05) with both the WTP for the extra QALY values using the EQ-5D-3L and the VAS methods. Educational level and monthly income also showed statistically significant relationships with the WTP for the additional QALY gained by the family members (p < 0.05). CONCLUSION: Our findings indicated that the participants' WTP value of the additional QALY gained from the hypothetical life-saving treatment was in the range of 0.20–0.24 of the gross domestic product (GDP) per capita of Iran. This value is far lower than the World Health Organization (WHO) recommended CE threshold value of one. This wide gap reflects the challenges the health system is facing and requires further research for defining the most appropriate CE threshold at the local level. BioMed Central 2020-10-23 /pmc/articles/PMC7585313/ /pubmed/33110399 http://dx.doi.org/10.1186/s12962-020-00241-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Moradi, Najmeh
Woldemichael, Abraha
Malekian, Parisa
Rotvandi, Delnia Moradi
Rezaei, Satar
An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran
title An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran
title_full An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran
title_fullStr An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran
title_full_unstemmed An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran
title_short An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran
title_sort exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western iran
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585313/
https://www.ncbi.nlm.nih.gov/pubmed/33110399
http://dx.doi.org/10.1186/s12962-020-00241-9
work_keys_str_mv AT moradinajmeh anexploratorystudytoestimatecosteffectivenessthresholdvalueforlifesavingtreatmentsinwesterniran
AT woldemichaelabraha anexploratorystudytoestimatecosteffectivenessthresholdvalueforlifesavingtreatmentsinwesterniran
AT malekianparisa anexploratorystudytoestimatecosteffectivenessthresholdvalueforlifesavingtreatmentsinwesterniran
AT rotvandidelniamoradi anexploratorystudytoestimatecosteffectivenessthresholdvalueforlifesavingtreatmentsinwesterniran
AT rezaeisatar anexploratorystudytoestimatecosteffectivenessthresholdvalueforlifesavingtreatmentsinwesterniran
AT moradinajmeh exploratorystudytoestimatecosteffectivenessthresholdvalueforlifesavingtreatmentsinwesterniran
AT woldemichaelabraha exploratorystudytoestimatecosteffectivenessthresholdvalueforlifesavingtreatmentsinwesterniran
AT malekianparisa exploratorystudytoestimatecosteffectivenessthresholdvalueforlifesavingtreatmentsinwesterniran
AT rotvandidelniamoradi exploratorystudytoestimatecosteffectivenessthresholdvalueforlifesavingtreatmentsinwesterniran
AT rezaeisatar exploratorystudytoestimatecosteffectivenessthresholdvalueforlifesavingtreatmentsinwesterniran